Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on adaptive closed-loop algorithms, FDA trial outcomes, and reimbursement risks make Beta Bionics filings challenging to navigate. If you have ever typed "Beta Bionics SEC filings explained simply" or wondered how clinical data shows up in a 10-K, you know the pain of wading through dense medical-device disclosures.
Stock Titan solves this by pairing every submission—whether a Beta Bionics annual report 10-K simplified or a Beta Bionics quarterly earnings report 10-Q filing—with AI-powered summaries that translate technical jargon into clear takeaways. Need to monitor Beta Bionics insider trading Form 4 transactions? Our engine flags Beta Bionics Form 4 insider transactions real-time, highlighting executive buys or sells. Curious about sudden news? The platform offers Beta Bionics 8-K material events explained within minutes of EDGAR release, plus quick links to management’s commentary.
With complete coverage of 10-K, 10-Q, 8-K, S-1, and proxy documents, Stock Titan lets you:
- Track Beta Bionics executive stock transactions Form 4 before market moves
- Perform Beta Bionics earnings report filing analysis without manual number crunching
- Review the Beta Bionics proxy statement executive compensation table in plain language
This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.
The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.
Beta Bionics reports that Sands Capital Life Sciences Pulse Fund II, Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 3,570,113 shares of common stock, equal to 8.2% of the class based on 43,470,125 shares outstanding as reported July 25, 2025. The filing shows 0 shares of sole voting or dispositive power and 3,570,113 shares of shared voting and dispositive power. The reporting parties file jointly and certify the holdings were not acquired to change or influence control of the issuer.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have filed a Schedule 13G disclosing beneficial ownership of approximately 2.93 million Beta Bionics (BBNX) common shares, representing 6.8 % of the outstanding class as of 30 June 2025. All voting (2.93 m) and dispositive (2.93 m) rights are reported as shared; the firms hold no sole authority.
The filing was made under Rule 13d-1(b), signalling a passive investment. Morgan Stanley is classified as a parent holding company (HC), while the subsidiary is a broker-dealer (BD). The certification states the position was acquired in the ordinary course of business and not to influence control. A near-7 % institutional stake from a globally recognised financial institution may enhance BBNX’s liquidity, analyst coverage and investor credibility.
Beta Bionics, Inc. (Nasdaq: BBNX) filed an 8-K to disclose materials from its first Investor & Analyst Event held on 22 June 2025 in conjunction with the ADA Scientific Sessions. Exhibit 99.1 contains a detailed slide deck highlighting two-year, real-world performance of the iLet Bionic Pancreas.
The company analysed data from 16,439 commercial users who uploaded ≥3 weeks of CGM readings between 19 May 2023 and 18 May 2025. A core cohort of 14,952 users with baseline HbA1c records showed an average HbA1c reduction from 8.9 % to a GMI of 7.3 %. Across multiple sub-groups—MDI converts (8,802 users), competitive HCL converts (2,910 users), endocrinology vs. primary-care settings, and “fully-closed loop” users—similar improvements were observed, with ≥83 % of patients meeting ADA hypoglycaemia targets (<4 % time <70 mg/dL; <1 % time <54 mg/dL).
Algorithmic performance data from 30,077 device sessions indicate the system reaches a steady-state GMI of 7.4 % within two days of initiation, underscoring rapid optimisation.
Management emphasises the potential clinical benefit of iLet but cautions that the forward-looking statements are subject to regulatory, financing and market risks. No financial metrics, revenue guidance or earnings updates were provided, and the furnished information is not deemed “filed” under the Exchange Act.
FAQ
What is the current stock price of Beta Bionics (BBNX)?
What is the market cap of Beta Bionics (BBNX)?
